杭州泰格医药科技股份有限公司2025年半年度报告摘要

Group 1 - The company will not distribute cash dividends, issue bonus shares, or increase capital from reserves during the reporting period [2] - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period [4][5] - The company approved the sale of a 95.09% stake in its associate company, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd., to Zhengda Pharmaceutical Investment (Beijing) Group Co., Ltd. for approximately $34.11 million [3]